BioInvest News – Nektar (NKTR) NKTR has signed the largest single product deal in biotech history with BMS for their leading I/O development candidate NKTR-214. Clearly BMS paid handsomely for what may have been the most attractive asset in the space.
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.